View Exam | PowerPak

1. All of the following are potential consequences of untreated HCV infection, EXCEPT:

A. Severe depression B. Liver carcinoma C. Cirrhosis D. Death

2. Which of the following investigational agents is a nucleotide analog that acts by inhibiting HCV viral RNA polymerase?

A. Sofosbuvir B. Daclatasvir C. Simeprevir D. Vaniprevir

3. All of the following statements regarding protease inhibitor therapy are true, EXCEPT:

A. Viral resistance to protease inhibitors can emerge within 24 hours B. Fixed duration combination therapy including protease inhibitors is recommended for patients classified as relapsers C. Patients with cirrhosis receiving protease inhibitor therapy require a longer duration of treatment versus patients without cirrhosis D. Anemia is a frequently reported adverse event in patients receiving protease inhibitor therapy

4. BD is a 62-year-old male recently diagnosed with HCV. He is currently receiving triple-drug therapy consisting of pegylated-interferon (PEG-IFN), ribavirin, and telaprevir. He has no history of any prior treatment for HCV. Four weeks after therapy initiation, BD's serum is negative for HCV RNA. At week 12, his HCV RNA levels remain undetectable. Which of the following is the MOST appropriate next step in therapy for BD?

A. Continue all therapies for an additional 36 weeks for a total of 48 weeks B. Discontinue all therapy and reassess HCV RNA in 12 weeks C. Continue only telaprevir for an additional 12 weeks for a total of 24 weeks D. Continue PEG-IFN and ribavirin only for an additional 12 weeks for a total of 24 weeks

5. In order to address shortcomings in current HCV treatments, all of the following emerging treatment regimens are currently being investigated, EXCEPT:

A. The inclusion of ribavirin in all future combination dosing B. Shorter treatment durations C. The elimination of food requirements D. The development of interferon-free protocols

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. All of the following are potential consequences of untreated HCV infection, EXCEPT:

2. Which of the following investigational agents is a nucleotide analog that acts by inhibiting HCV viral RNA polymerase?

3. All of the following statements regarding protease inhibitor therapy are true, EXCEPT:

5. In order to address shortcomings in current HCV treatments, all of the following emerging treatment regimens are currently being investigated, EXCEPT:

« Return to Activity

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. All of the following are potential consequences of untreated HCV infection, EXCEPT:

2. Which of the following investigational agents is a nucleotide analog that acts by inhibiting HCV viral RNA polymerase?

3. All of the following statements regarding protease inhibitor therapy are true, EXCEPT:

5. In order to address shortcomings in current HCV treatments, all of the following emerging treatment regimens are currently being investigated, EXCEPT:

« Return to Activity

Customers who Purchased
this Activity also Purchased